Regeneron Pharmaceuticals (REGN) Cash & Equivalents (2009 - 2026)

Regeneron Pharmaceuticals' Cash & Equivalents history runs 18 years deep, the most recent figure standing at $2.5 billion for Q2 2026.

• In Q2 2026, Cash & Equivalents rose 23.05% year-over-year to $2.5 billion; the TTM figure through Jun 2026 stood at $2.5 billion (up 23.05% YoY), while the FY2025 annual figure was $3.1 billion, up 25.32% from the prior year.
• Cash & Equivalents for Q2 2026 stood at $2.5 billion, down from $3.0 billion in the prior quarter.
• The five-year high for Cash & Equivalents was $3.9 billion in Q1 2023, with the low at $1.9 billion in Q2 2024.
• The 5-year median for Cash & Equivalents is $2.7 billion (2023), against an average of $2.7 billion.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents surged 132.68% in 2022, then slumped 42.94% in 2023.
• Regeneron Pharmaceuticals' Cash & Equivalents stood at $3.1 billion in 2022, then decreased by 12.1% to $2.7 billion in 2023, then fell by 8.86% to $2.5 billion in 2024, then gained by 25.32% to $3.1 billion in 2025, then declined by 21.24% to $2.5 billion in 2026.
• Business Quant data shows REGN's Cash & Equivalents at $2.5 billion in Q2 2026, $3.0 billion in Q1 2026, and $3.1 billion in Q4 2025.